504 related articles for article (PubMed ID: 12414858)
21. The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting.
White KE; Jonsson KB; Carn G; Hampson G; Spector TD; Mannstadt M; Lorenz-Depiereux B; Miyauchi A; Yang IM; Ljunggren O; Meitinger T; Strom TM; Jüppner H; Econs MJ
J Clin Endocrinol Metab; 2001 Feb; 86(2):497-500. PubMed ID: 11157998
[TBL] [Abstract][Full Text] [Related]
22. Iron replacement ameliorates hypophosphatemia in autosomal dominant hypophosphatemic rickets: A review of the role of iron.
Menon LP; Weinstein RS
Bone; 2020 Feb; 131():115137. PubMed ID: 31756522
[TBL] [Abstract][Full Text] [Related]
23. Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia.
Imel EA; Peacock M; Pitukcheewanont P; Heller HJ; Ward LM; Shulman D; Kassem M; Rackoff P; Zimering M; Dalkin A; Drobny E; Colussi G; Shaker JL; Hoogendoorn EH; Hui SL; Econs MJ
J Clin Endocrinol Metab; 2006 Jun; 91(6):2055-61. PubMed ID: 16551733
[TBL] [Abstract][Full Text] [Related]
24. Fibroblast growth factor (FGF)-23 and hypophosphatemic rickets/osteomalacia.
Fukumoto S; Yamashita T
Endocr J; 2001 Dec; 48(6):603-10. PubMed ID: 11873859
[No Abstract] [Full Text] [Related]
25. Fibroblast growth factor 23 and its receptors.
Yu X; White KE
Ther Apher Dial; 2005 Aug; 9(4):308-12. PubMed ID: 16076372
[TBL] [Abstract][Full Text] [Related]
26. Hypophosphatemic rickets and osteomalacia.
de Menezes Filho H; de Castro LC; Damiani D
Arq Bras Endocrinol Metabol; 2006 Aug; 50(4):802-13. PubMed ID: 17117305
[TBL] [Abstract][Full Text] [Related]
27. [Fibroblast growth factor (FGF) 23 works as a phosphate-regulating hormone and is involved in the pathogenesis of several disorders of phosphate metabolism].
Fukumoto S
Rinsho Byori; 2007 Jun; 55(6):555-9. PubMed ID: 17657990
[TBL] [Abstract][Full Text] [Related]
28. [Hereditary hypophosphatemia in adults].
Vélayoudom-Céphise FL; Vantyghem MC; Wémeau JL
Presse Med; 2005 Dec; 34(22 Pt 1):1720-6. PubMed ID: 16374396
[TBL] [Abstract][Full Text] [Related]
29. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis.
Larsson T; Marsell R; Schipani E; Ohlsson C; Ljunggren O; Tenenhouse HS; Jüppner H; Jonsson KB
Endocrinology; 2004 Jul; 145(7):3087-94. PubMed ID: 14988389
[TBL] [Abstract][Full Text] [Related]
30. Hypophosphatemic rickets/osteomalacia in linear sebaceous nevus syndrome: a variant of tumor-induced osteomalacia.
Carey DE; Drezner MK; Hamdan JA; Mange M; Ahmad MS; Mubarak S; Nyhan WL
J Pediatr; 1986 Dec; 109(6):994-1000. PubMed ID: 3023599
[TBL] [Abstract][Full Text] [Related]
31. FGF23-related hypophosphatemic rickets/osteomalacia: diagnosis and new treatment.
Fukumoto S
J Mol Endocrinol; 2021 Feb; 66(2):R57-R65. PubMed ID: 33295878
[TBL] [Abstract][Full Text] [Related]
32. [FGF-23 on hypophosphatemic rickets/osteomalacia].
Imanishi Y
Clin Calcium; 2002 May; 12(5):634-7. PubMed ID: 15775350
[TBL] [Abstract][Full Text] [Related]
33. Cinacalcet in the management of tumor-induced osteomalacia.
Geller JL; Khosravi A; Kelly MH; Riminucci M; Adams JS; Collins MT
J Bone Miner Res; 2007 Jun; 22(6):931-7. PubMed ID: 17352646
[TBL] [Abstract][Full Text] [Related]
34. FGF23 and disorders of phosphate homeostasis.
Yu X; White KE
Cytokine Growth Factor Rev; 2005 Apr; 16(2):221-32. PubMed ID: 15863037
[TBL] [Abstract][Full Text] [Related]
35. Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment.
Endo I; Fukumoto S; Ozono K; Namba N; Inoue D; Okazaki R; Yamauchi M; Sugimoto T; Minagawa M; Michigami T; Nagai M; Matsumoto T
Endocr J; 2015; 62(9):811-6. PubMed ID: 26135520
[TBL] [Abstract][Full Text] [Related]
36. [Updates on rickets and osteomalacia: FGF23-mediated hypophosphatemic rickets/osteomalacia].
Michigami T
Clin Calcium; 2013 Oct; 23(10):1429-35. PubMed ID: 24076640
[TBL] [Abstract][Full Text] [Related]
37. The role of fibroblast growth factor 23 for hypophosphatemia and abnormal regulation of vitamin D metabolism in patients with McCune-Albright syndrome.
Yamamoto T; Imanishi Y; Kinoshita E; Nakagomi Y; Shimizu N; Miyauchi A; Satomura K; Koshiyama H; Inaba M; Nishizawa Y; Jüppner H; Ozono K
J Bone Miner Metab; 2005; 23(3):231-7. PubMed ID: 15838626
[TBL] [Abstract][Full Text] [Related]
38. Induction of FGF23-related hypophosphatemic osteomalacia by alcohol consumption.
Hidaka N; Kato H; Koga M; Katsura M; Oyama Y; Kinoshita Y; Fukumoto S; Makita N; Nangaku M; Ito N
Bone Rep; 2021 Dec; 15():101144. PubMed ID: 34901334
[TBL] [Abstract][Full Text] [Related]
39. FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate.
Bowe AE; Finnegan R; Jan de Beur SM; Cho J; Levine MA; Kumar R; Schiavi SC
Biochem Biophys Res Commun; 2001 Jun; 284(4):977-81. PubMed ID: 11409890
[TBL] [Abstract][Full Text] [Related]
40. [FGF23 and bone metabolism].
Ito N; Fukumoto S
Clin Calcium; 2005 Jul; 15(7):43-8. PubMed ID: 15995295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
